What you’ll learn in the whitepaper:
This paper illustrates how unFAIR (ambiguously defined data and protocols) adversely affects every aspect of communication in the drug discovery industry — from internal workflows, to external collaborations with CROs and service providers.
You will learn the importance of FAIR data, the ongoing efforts to de-risk collaboration and data exchange, and what it will take for FAIR principles to be more ubiquitously adopted.